Cue Biopharma (CUE) EBITDA Margin (2018 - 2026)

Cue Biopharma has disclosed EBITDA Margin across 9 years of filings, most recently posting 1113.3% for Q2 2026.

• In Q2 2026, EBITDA Margin fell 82099.0% year-over-year to 1113.3%; the TTM figure through Jun 2026 stood at 453.5% (up 2173.0% YoY), while the FY2025 annual figure was 96.67%, up 35019.0% from the prior year.
• EBITDA Margin came in at 1113.3% for Q2 2026 at Cue Biopharma, down from 20.82% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 20.82% in Q4 2025 to a low of 50346.15% in Q2 2022.
• Average EBITDA Margin over 5 years is 5525.71%, with a median of 759.58% recorded in 2023.
• Year-over-year, EBITDA Margin tumbled 4996999 bps in 2022 and soared 4936808 bps in 2023.
• Over 5 years, EBITDA Margin stood at 9845.03% in 2022, then soared by 92 bps to 759.58% in 2023, then advanced by 20 bps to 611.23% in 2024, then soared by 103 bps to 20.82% in 2025, then tumbled by 5447 bps to 1113.3% in 2026.
• Per Business Quant data, the three most recent EBITDA Margin figures were 1113.3% in Q2 2026, 20.82% in Q4 2025, and 353.42% in Q3 2025.